サンプル依頼リスト カート
  • English
デフォルト表紙
市場調査レポート
商品コード
1751295

米国の馬の再生医療市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、州別、セグメント別予測、2025年～2030年

U.S. Equine Regenerative Medicine Market Size, Share & Trends Analysis Report By Product (Stem Cells, Platelet-Rich Plasma (PRP)), By Application, By End Use, By State, And Segment Forecasts, 2025 - 2030

出版日
ページ情報
英文 100 Pages
納期
2～10営業日
カスタマイズ可能
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.35円
米国の馬の再生医療市場規模、シェア、動向分析レポート：製品別、用途別、最終用途別、州別、セグメント別予測、2025年～2030年
出版日: 2025年05月21日
発行: Grand View Research
ページ情報: 英文 100 Pages
納期: 2～10営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 図表
  • 目次
概要

米国の馬の再生医療市場の成長と動向

Grand View Research, Inc.の最新レポートによると、米国の馬の再生医療市場規模は2030年までに8,044万米ドルに達し、予測期間中のCAGRは8.31％を記録すると予測されています。

市場成長を促進する主要因は、スポーツ＆パフォーマンス馬における筋骨格系損傷の有病率の増加、馬の保険＆診療モデルへの再生医療の統合の拡大、馬の再生医療における進歩、ペットの人間化と馬主の消費意欲の高まりです。

腱炎、靭帯断裂、関節損傷、変形性関節症などの筋骨格系の傷害は、米国のスポーツ馬やパフォーマンス馬の間でますます一般的になっています。障害飛越、馬場馬術、バレルレース、エンデュランスレースのような馬術競技の増加により、馬は肉体的な限界まで追い込まれ、軟部組織や関節の損傷、その他の関連合併症のリスクが高まっています。従来型治療法（非ステロイド性消炎鎮痛剤や手術など）では、治癒が不完全で再受傷率が高いことが多いです。多血小板血漿（多血小板血漿）、幹細胞療法、プロストライド（自己タンパク質溶液）などの再生療法は、細胞レベルで組織の修復を促進する能力があるため、人気を集めています。これらのアプローチは回復を早め、馬の運動能力を完全に回復させ、再発のリスクを減らすことができます。

例えば、競走馬やジャンパーによく見られる傷害である懸垂靭帯脱落症の治療に、間葉系幹細胞（MSC）療法が採用されるようになってきています。研究によると、MSCは炎症を抑え、腱繊維の配列を改善し、より完全な治癒に導くことができます。クリニックや発表病院では現在、このような治療が標準的に行われており、傷害の流行による市場の力強い成長を示しています。

さらに、獣医療的再生医療における科学的イノベーションが市場を前進させています。過去10年間で、幹細胞や生物学的薬剤を分離、拡大、送達する技術は、より効率的で、費用対効果に優れ、スケーラブルになりました。細胞生物学、組織工学、生体材料を理解することで、治療成績が向上し、応用範囲も広がっています。

Equine Network LLCが2025年2月に発表したデータによると、注射金療法（GOLDIC）は馬の変形性関節症（OA）やその他の筋骨格系疾患に対する有望な治療法として浮上しています。馬の血液を親水性の金粒子とインキュベートすることで、炎症を抑え再生を促進するサイトカインや成長因子を豊富に含む血清が得られます。最近の研究では、GOLDICは馬の跛行、関節液貯留、腫脹の症状を有意に改善し、その多くは3～6ヵ月後には無症状となりました。GOLDICは、従来型治療法に比べて長期にわたって症状を改善する革新的な治療法であり、よりサステイナブル解決策を求める獣医師や馬主の間で支持を集める可能性があります。炎症を抑え、組織の再生を促進する効果が証明されているGOLDICは、馬のセグメントでより先進的な整形生物学的治療の採用を促す可能性があります。これは再生治療への需要を高め、より多くの投資を呼び込み、馬の様々な筋骨格系や軟部組織の損傷に対する同様の治療法の開発に影響を与える可能性があります。

米国の馬の再生医療市場レポートハイライト

  • 製品別では、幹細胞セグメントが2024年に61.75%の最大市場シェアを占めました。これは、適切な組織再生を促進し、治癒の質を向上させ、関節、腱、靭帯の損傷における瘢痕形成を減少させる能力があるためと考えられます。ベーリンガーによるGlobal Stem Cell Technologyの買収のような戦略的投資は、幹細胞を将来の馬ヘルスケアにおける礎石と位置づけ、イノベーションをさらに加速させています。
  • 用途別では、外傷・創傷治療セグメントが予測期間中最も速いCAGR 8.65％で成長すると予想されています。これは、傷害の発生率の上昇と馬の健康に対する意識の高まりによるものです。幹細胞、多血小板血漿、自己タンパク質溶液、IRAP、羊膜由来製品などの再生療法における革新は、治癒を著しく改善し、創傷の瘢痕を減少させています。ザラシルの高度創傷治療製剤のような製品は、科学的裏付けのある再生ソリューションの可能性を示しています。このような急速な技術進歩により、外傷ケアは今後の市場成長の重要な促進要因に位置づけられます。
  • 最終用途別では、予測期間中にCAGR 8.75%で最も急成長すると予想されるのは獣医療研究機関です。これは、技術革新と臨床検証において極めて重要な役割を担っているためです。彼らの調査は、再生治療の安全性と有効性を裏付ける重要な証拠を提供し、より広範な臨床採用を促しています。組織修復と疾病予防におけるブレークスルーを推進することで、これらの研究機関は馬のヘルスケアの未来を形成しています。
  • 2024年の市場シェアはテキサス州が16.61％で圧倒的です。非侵襲的な治療や幹細胞・多血小板血漿療法の技術革新に対する需要の高まり、馬の飼育数が多いことなどが要因となり、急成長が見込まれています。Ardent EquineとPegasus Orthobiologicsの提携や、Vetirus PharmaceuticalsによるEnso Discoveriesの買収のように、バイオテクノロジー企業と獣医療機関との戦略的提携、買収、共同研究は、技術革新と治療開発をさらに強化し、フロリダをこのセグメントのリーダーとして位置づけています。

目次

第1章 調査手法と範囲

第2章 エグゼクティブサマリー

第3章 北米の馬の再生医療市場の変数、動向、範囲

  • 市場系統の展望
    • 親市場の展望
    • 補助市場の展望
  • 市場力学
    • 市場促進要因分析
    • 市場抑制要因分析
    • 市場機会分析
    • 市場課題分析
    • 産業分析-ポーターのファイブフォース分析
    • PESTEL分析
  • 2024年における米国主要州の馬の推定頭数
  • 規制の枠組み
  • 米国の馬産業の人口統計
    • 品種タイプ
    • 活動タイプ（スポーツなど）
    • 馬術産業の事実と数字
  • 製品別価格分析
  • 製品パイプライン分析/臨床検査分析
  • 保険適用範囲分析

第4章 米国の馬の再生医療市場：製品別、推定・動向分析

  • セグメントダッシュボード
  • 米国の馬の再生医療市場：製品変動分析、100万米ドル、2024年と2030年
    • 幹細胞
    • 多血小板血漿（多血小板血漿）
    • その他

第5章 米国の馬の再生医療市場：用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国の馬の再生医療市場：用途別変動分析、100万米ドル、2024年と2030年
    • 整形外科
    • 外傷/創傷ケア
    • その他

第6章 米国の馬の再生医療市場：最終用途別、推定・動向分析

  • セグメントダッシュボード
  • 米国の馬の再生医療市場：最終用途変動分析、100万米ドル、2024年と2030年
    • 動物病院/クリニック
    • 獣医研究機関
    • その他

第7章 米国の馬の再生医療市場：州推定・動向分析

  • 州別市場シェア分析、2024年と2030年
  • 州市場ダッシュボード
  • 州市場のスナップショット
  • 市場規模、予測、動向分析、2018～2030年
  • 米国
    • テキサス
    • カリフォルニア
    • フロリダ
    • オハイオ州
    • オクラホマ
    • ケンタッキー州
    • ミズーリ州
    • ペンシルベニア州
    • コロラド州
    • その他の州

第8章 競合情勢

  • 企業参加者の分類
  • 企業の市況分析/ヒートマップ分析
  • 企業プロファイル
    • Boehringer Ingelheim International GmbH
    • Zoetis
    • Dechra Pharmaceuticals Plc
    • Equine Amnio Solutions
    • VetStem, Inc.
    • Hilltop Bio
    • Equi-Stem LLC
    • Ardent Equine
    • Pronoia BIoTech
    • Medrego
    • AniCell BioTech
    • PetVivo Holdings, Inc.（Spyrng）
    • Arthrex Inc.
    • Contura Vet
    • Nucleus ProVets LLC
    • Enso Discoveries（Vetirus Pharmaceuticals）
    • Gallant Therapeutics
    • Astaria Global
    • Interpath Global（4CYTE）
    • American Regent, Inc.
  • 戦略マッピング
    • 合併と買収
    • パートナーシップとコラボレーション
    • 拡大
    • 製品発売
    • その他
  • その他の主要参入企業一覧
図表

List of Tables

  • Table 1. List of Secondary Sources
  • Table 2. List of Abbreviations
  • Table 3. Estimated Equine Population in U.S. key states, 2024.
  • Table 4. Pricing analysis by key products
  • Table 5. U.S. Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 6. U.S. Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 7. U.S. Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 8. U.S. Equine Regenerative Medicine Market, by State, 2018 - 2030 (USD Million)
  • Table 9. Texas Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 10. Texas Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 11. Texas Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 12. California Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 13. California Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 14. California Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 15. Florida Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 16. Florida Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 17. Florida Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 18. Ohio Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 19. Ohio Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 20. Ohio Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 21. Oklahoma Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 22. Oklahoma Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 23. Oklahoma Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 24. Kentucky Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 25. Kentucky Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 26. Kentucky Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 27. Missouri Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 28. Missouri Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 29. Missouri Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 30. Pennsylvania Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 31. Pennsylvania Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 32. Pennsylvania Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 33. Colorado Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 34. Colorado Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 35. Colorado Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 36. Other States Equine Regenerative Medicine Market, By Product, 2018 - 2030 (USD Million)
  • Table 37. Other States Equine Regenerative Medicine Market, By Application, 2018 - 2030 (USD Million)
  • Table 38. Other States Equine Regenerative Medicine Market, By End Use, 2018 - 2030 (USD Million)
  • Table 39. Company Overview
  • Table 40. Product Benchmarking
  • Table 41. Financial Performance
  • Table 42. Strategic Initiatives

List of Figures

  • Fig. 1 Market research process
  • Fig. 2 Information Procurement
  • Fig. 3 Primary Research Pattern
  • Fig. 4 Market Research Approaches
  • Fig. 5 Value Chain-Based Sizing & Forecasting
  • Fig. 6 Market Formulation & Validation
  • Fig. 7 Equine Regenerative Medicine Market, Market Segmentation
  • Fig. 8 Market Driver Relevance Analysis (Current & Future Impact)
  • Fig. 9 Market Restraint Relevance Analysis (Current & Future Impact)
  • Fig. 10 Market Challenge Relevance Analysis (Current & Future Impact)
  • Fig. 11 SWOT Analysis, By Factor (Political & Legal, Economic and Technological)
  • Fig. 12 Porter's Five Forces Analysis
  • Fig. 13 State Marketplace: Key Takeaways
  • Fig. 14 U.S. Equine Regenerative Medicine Market, for Product, 2018 - 2030 (USD Million)
  • Fig. 15 U.S. Equine Regenerative Medicine Market, for Stem Cells, 2018 - 2030 (USD Million)
  • Fig. 16 U.S. Equine Regenerative Medicine Market, for Platelet-Rich Plasma (PRP), 2018 - 2030 (USD Million)
  • Fig. 17 U.S. Equine Regenerative Medicine Market, for Others , 2018 - 2030 (USD Million)
  • Fig. 18 U.S. Equine Regenerative Medicine Market, for Application, 2018 - 2030 (USD Million)
  • Fig. 19 U.S. Equine Regenerative Medicine Market, for Orthopedics, 2018 - 2030 (USD Million)
  • Fig. 20 U.S. Equine Regenerative Medicine Market, for Trauma/Wound Care, 2018 - 2030 (USD Million)
  • Fig. 21 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 22 U.S. Equine Regenerative Medicine Market, for End Use, 2018 - 2030 (USD Million)
  • Fig. 23 U.S. Equine Regenerative Medicine Market, for Veterinary Hospitals/Clinics, 2018 - 2030 (USD Million)
  • Fig. 24 U.S. Equine Regenerative Medicine Market, for Veterinary Research Institutes, 2018 - 2030 (USD Million)
  • Fig. 25 U.S. Equine Regenerative Medicine Market, for Others, 2018 - 2030 (USD Million)
  • Fig. 26 State Outlook, 2024 & 2030
  • Fig. 27 Texas Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 28 California Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 29 Florida Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 30 Ohio Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 31 Oklahoma Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 32 Kentucky Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 33 Missouri Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 34 Pennsylvania Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 35 Colorado Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 36 Other States Equine Regenerative Medicine Market, 2018 - 2030 (USD Million)
  • Fig. 37 Market participant categorization
  • Fig. 38 Heat map analysis
  • Fig. 39 Strategic Framework
目次
Product Code: GVR-4-68040-586-8

U.S. Equine Regenerative Medicine Market Growth & Trends:

The U.S. equine regenerative medicine market size is expected to reach USD 80.44 million by 2030, registering a CAGR of 8.31% over the forecast period, according to a new report by Grand View Research, Inc. The primary factors driving the market growth are the increasing prevalence of musculoskeletal injuries in sport & performance horses, the growing integration of regenerative medicine into equine insurance & practice models, advancements in equine regenerative medicine, and the growing pet humanization & equine owner willingness to spend.

Musculoskeletal injuries such as tendonitis, ligament tears, joint damage, and osteoarthritis are increasingly common among sport and performance horses in the U.S. These injuries significantly reduce performance ability, lead to prolonged recovery, and may end careers prematurely. The rise in competitive equestrian events like show jumping, dressage, barrel racing, and endurance racing pushes horses to their physical limits, increasing the risk of soft tissue, joint injuries and other related complications. Traditional therapies (like NSAIDs, surgery) often result in incomplete healing and high rates of re-injury. Regenerative therapies, including platelet-rich plasma (PRP), stem cell therapy, and Pro-Stride (autologous protein solution), are gaining traction due to their ability to enhance tissue repair at the cellular level. These approaches promote faster recovery and can restore the horse to full athletic performance, reducing the risk of recurrence.

An example is the increased adoption of mesenchymal stem cell (MSC) therapy to treat suspensory ligament desmitis, a common injury in racehorses and jumpers. Studies show MSCs can reduce inflammation and improve tendon fiber alignment, leading to more complete healing. Clinics and referral hospitals now offer such treatments as standard, indicating strong market growth based on injury prevalence.

Furthermore, scientific innovations in veterinary regenerative medicine propel the market forward. Over the past decade, techniques for isolating, expanding, and delivering stem cells or biologic agents have become more efficient, cost-effective, and scalable. Understanding cell biology, tissue engineering, and biomaterials has improved treatment outcomes and broadened applications.

As per data published in February 2025 by Equine Network LLC, injectable gold therapy (GOLDIC) is emerging as a promising treatment for equine osteoarthritis (OA) and other musculoskeletal conditions. By incubating the horse's blood with hydrophilic gold particles, the therapy produces a serum rich in cytokines and growth factors that help reduce inflammation and promote regeneration. In a recent study, GOLDIC significantly improved symptoms of lameness, joint effusion, and swelling in horses, with many becoming asymptomatic after three to six months. As an innovative therapy that offers long-term relief compared to traditional treatments, it could gain traction among veterinarians and horse owners looking for more sustainable solutions. With proven efficacy in reducing inflammation and enhancing tissue regeneration, GOLDIC might encourage the adoption of more advanced orthobiologic treatments in the equine sector. This could increase demand for regenerative therapies, attracting more investment and potentially influencing the development of similar treatments for various musculoskeletal and soft tissue injuries in horses.

U.S. Equine Regenerative Medicine Market Report Highlights:

  • Based on product, the stem cells segment held the largest market share of 61.75% in 2024. This can be attributed to its ability to promote proper tissue regeneration, improve healing quality, and reduce scar formation in joint, tendon, and ligament injuries. Strategic investments, such as Boehringer's acquisition of Global Stem Cell Technology, further accelerate innovation, positioning stem cells as a cornerstone of future equine healthcare.
  • Based on application, the trauma/ wound care segment is expected to grow at the fastest CAGR of 8.65% over the forecast period. This can be attributed to the rising incidence of injuries and increasing awareness of equine health. Innovations in regenerative therapies-such as stem cells, PRP, autologous protein solutions, IRAP, and amniotic-derived products-significantly improve healing and reduce wound scarring. Products like Zarasyl's advanced wound care formulations showcase the potential of science-backed regenerative solutions. This rapid technological advancement positions trauma care as a key driver of future market growth
  • By end use, the veterinary research institutes segment is expected to grow at the fastest CAGR of 8.75% during the forecast period. This can be owed to their pivotal role in innovation and clinical validation. Their research provides critical evidence supporting the safety and efficacy of regenerative treatments, encouraging wider clinical adoption. By driving breakthroughs in tissue repair and disease prevention, these institutes are shaping the future of equine healthcare.
  • The state of Texas dominated the market in 2024 with a share of 16.61%. It is expected to grow rapidly, driven by rising demand for non-invasive treatments and innovations in stem cell and PRP therapies, and the presence of a large horse population. Strategic partnerships, acquisitions, and collaborations between biotech companies and veterinary institutions, like Ardent Equine's partnership with Pegasus Orthobiologics and Vetirus Pharmaceuticals' acquisition of Enso Discoveries, further enhance innovation and therapy development, positioning Florida as a leader in the sector.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definition
  • 1.3. Research Methodology
  • 1.4. Information Procurement
    • 1.4.1. Purchased Database
    • 1.4.2. GVR's Internal Database
    • 1.4.3. Secondary Sources
    • 1.4.4. Primary Research
  • 1.5. Information/Data Analysis
  • 1.6. Market Formulation & Visualization
  • 1.7. Data Validation & Publishing
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
    • 1.8.2. Volume Price Analysis
    • 1.8.3. Global Market: CAGR Calculation
  • 1.9. List of Secondary Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. North America Companion Animal Medicine Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
    • 3.1.1. Parent Market Outlook
    • 3.1.2. Ancillary Market Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
      • 3.2.1.1. Increasing Prevalence of Musculoskeletal Injuries in Sport and Performance Horses
      • 3.2.1.2. Increasing Integration of Regenerative Medicine into Equine Insurance and Practice Models
      • 3.2.1.3. Advancements in Equine Regenerative Medicine
      • 3.2.1.4. Growing Pet Humanization and Equine Owner Willingness to Spend
    • 3.2.2. Market Restraint Analysis
      • 3.2.2.1. High Cost of Regenerative Therapies
      • 3.2.2.2. Regulatory Ambiguity and Lack of Standardization
    • 3.2.3. Market Opportunity Analysis
    • 3.2.4. Market Challenge Analysis
    • 3.2.5. Industry Analysis - Porter's
      • 3.2.5.1. Bargaining power of the suppliers
      • 3.2.5.2. Bargaining power of the buyers
      • 3.2.5.3. Threats of substitution
      • 3.2.5.4. Threats from new entrants
      • 3.2.5.5. Competitive rivalry
    • 3.2.6. PESTEL Analysis
      • 3.2.6.1. Political landscape
      • 3.2.6.2. Economic and Social landscape
      • 3.2.6.3. Technological landscape
  • 3.3. Estimated Equine Population in U.S. Key States, 2024
  • 3.4. Regulatory Framework
  • 3.5. Equine Industry Demographics in the U.S.
    • 3.5.1. Type of Breeds
    • 3.5.2. Type of Activity (Sports & Others)
    • 3.5.3. Equestrian Industry Facts & Figures
  • 3.6. Pricing Analysis, by Product
  • 3.7. Product Pipeline Analysis/Clinical Trials Analysis
  • 3.8. Insurance Coverage Analysis

Chapter 4. U.S. Equine Regenerative Medicine Market: Product Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. U.S. Equine Regenerative Medicine Market: By Product Movement Analysis, USD Million, 2024 & 2030
    • 4.2.1. Stem Cells
      • 4.2.1.1. Stem Cells Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.2. Platelet-Rich Plasma (PRP)
      • 4.2.2.1. Platelet-Rich Plasma (PRP) Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 4.2.3. Others
      • 4.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 5. U.S. Equine Regenerative Medicine Market: Application Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. U.S. Equine Regenerative Medicine Market: By Application Movement Analysis, USD Million, 2024 & 2030
    • 5.2.1. Orthopedics
      • 5.2.1.1. Orthopedics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.2. Trauma/ Wound Care
      • 5.2.2.1. Trauma/ Wound Care Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 5.2.3. Others
      • 5.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 6. U.S. Equine Regenerative Medicine Market: End Use Estimates & Trend Analysis

  • 6.1. Segment Dashboard
  • 6.2. U.S. Equine Regenerative Medicine Market: By End Use Movement Analysis, USD Million, 2024 & 2030
    • 6.2.1. Veterinary Hospitals/Clinics
      • 6.2.1.1. Veterinary Hospitals/Clinics Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. Veterinary Research Institutes
      • 6.2.2.1. Veterinary Research Institutes Market Estimates And Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Others
      • 6.2.3.1. Others Market Estimates And Forecasts, 2018 - 2030 (USD Million)

Chapter 7. U.S. Equine Regenerative Medicine Market: State Estimates & Trend Analysis

  • 7.1. State Market Share Analysis, 2024 & 2030
  • 7.2. State Market Dashboard
  • 7.3. State Market Snapshot
  • 7.4. Market Size, & Forecasts, Trend Analysis, 2018 to 2030:
  • 7.5. U.S.
    • 7.5.1. U.S. market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.2. Texas
      • 7.5.2.1. Texas market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.3. California
      • 7.5.3.1. California market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.4. Florida
      • 7.5.4.1. Florida market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.5. Ohio
      • 7.5.5.1. Ohio market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.6. Oklahoma
      • 7.5.6.1. Oklahoma market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.7. Kentucky
      • 7.5.7.1. Kentucky market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.8. Missouri
      • 7.5.8.1. Missouri market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.9. Pennsylvania
      • 7.5.9.1. Pennsylvania market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.10. Colorado
      • 7.5.10.1. Colorado market estimates and forecasts 2018 to 2030 (USD Million)
    • 7.5.11. Other States
      • 7.5.11.1. Other States market estimates and forecasts 2018 to 2030 (USD Million)

Chapter 8. Competitive Landscape

  • 8.1. Company Participant Categorization
  • 8.2. Company Market Position Analysis/ Heat Map Analysis
  • 8.3. Company Profile
    • 8.3.1. Boehringer Ingelheim International GmbH
      • 8.3.1.1. Company overview
      • 8.3.1.2. Financial performance
      • 8.3.1.3. Product benchmarking
      • 8.3.1.4. Strategic initiatives
    • 8.3.2. Zoetis
      • 8.3.2.1. Company overview
      • 8.3.2.2. Financial performance
      • 8.3.2.3. Product benchmarking
      • 8.3.2.4. Strategic initiatives
    • 8.3.3. Dechra Pharmaceuticals Plc
      • 8.3.3.1. Company overview
      • 8.3.3.2. Financial performance
      • 8.3.3.3. Product benchmarking
      • 8.3.3.4. Strategic initiatives
    • 8.3.4. Equine Amnio Solutions
      • 8.3.4.1. Company overview
      • 8.3.4.2. Financial performance
      • 8.3.4.3. Product benchmarking
      • 8.3.4.4. Strategic initiatives
    • 8.3.5. VetStem, Inc.
      • 8.3.5.1. Company overview
      • 8.3.5.2. Financial performance
      • 8.3.5.3. Product benchmarking
      • 8.3.5.4. Strategic initiatives
    • 8.3.6. Hilltop Bio
      • 8.3.6.1. Company overview
      • 8.3.6.2. Financial performance
      • 8.3.6.3. Product benchmarking
      • 8.3.6.4. Strategic initiatives
    • 8.3.7. Equi-Stem LLC
      • 8.3.7.1. Company overview
      • 8.3.7.2. Financial performance
      • 8.3.7.3. Product benchmarking
      • 8.3.7.4. Strategic initiatives
    • 8.3.8. Ardent Equine
      • 8.3.8.1. Company overview
      • 8.3.8.2. Financial performance
      • 8.3.8.3. Product benchmarking
      • 8.3.8.4. Strategic initiatives
    • 8.3.9. Pronoia Biotech
      • 8.3.9.1. Company overview
      • 8.3.9.2. Financial performance
      • 8.3.9.3. Product benchmarking
      • 8.3.9.4. Strategic initiatives
    • 8.3.10. Medrego
      • 8.3.10.1. Company overview
      • 8.3.10.2. Financial performance
      • 8.3.10.3. Product benchmarking
      • 8.3.10.4. Strategic initiatives
    • 8.3.11. AniCell BioTech
      • 8.3.11.1. Company overview
      • 8.3.11.2. Financial performance
      • 8.3.11.3. Product benchmarking
      • 8.3.11.4. Strategic initiatives
    • 8.3.12. PetVivo Holdings, Inc. (Spyrng)
      • 8.3.12.1. Company overview
      • 8.3.12.2. Financial performance
      • 8.3.12.3. Product benchmarking
      • 8.3.12.4. Strategic initiatives
    • 8.3.13. Arthrex Inc.
      • 8.3.13.1. Company overview
      • 8.3.13.2. Financial performance
      • 8.3.13.3. Product benchmarking
      • 8.3.13.4. Strategic initiatives
    • 8.3.14. Contura Vet
      • 8.3.14.1. Company overview
      • 8.3.14.2. Financial performance
      • 8.3.14.3. Product benchmarking
      • 8.3.14.4. Strategic initiatives
    • 8.3.15. Nucleus ProVets LLC
      • 8.3.15.1. Company overview
      • 8.3.15.2. Financial performance
      • 8.3.15.3. Product benchmarking
      • 8.3.15.4. Strategic initiatives
    • 8.3.16. Enso Discoveries (Vetirus Pharmaceuticals)
      • 8.3.16.1. Company overview
      • 8.3.16.2. Financial performance
      • 8.3.16.3. Product benchmarking
      • 8.3.16.4. Strategic initiatives
    • 8.3.17. Gallant Therapeutics
      • 8.3.17.1. Company overview
      • 8.3.17.2. Financial performance
      • 8.3.17.3. Product benchmarking
      • 8.3.17.4. Strategic initiatives
    • 8.3.18. Astaria Global
      • 8.3.18.1. Company overview
      • 8.3.18.2. Financial performance
      • 8.3.18.3. Product benchmarking
      • 8.3.18.4. Strategic initiatives
    • 8.3.19. Interpath Global (4CYTE)
      • 8.3.19.1. Company overview
      • 8.3.19.2. Financial performance
      • 8.3.19.3. Product benchmarking
      • 8.3.19.4. Strategic initiatives
    • 8.3.20. American Regent, Inc.
      • 8.3.20.1. Company overview
      • 8.3.20.2. Financial performance
      • 8.3.20.3. Product benchmarking
      • 8.3.20.4. Strategic initiatives
  • 8.4. Strategy Mapping
    • 8.4.1. Mergers & Acquisitions
    • 8.4.2. Partnerships & Collaborations
    • 8.4.3. Expansion
    • 8.4.4. Product launch
    • 8.4.5. Others
  • 8.5. List of other Key players